Drugs / Universal Donor Natural Killer Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05503134 | Feb 2022 → Feb 2027 expected | acute myeloid leukemia | Nationwide Children's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal Donor Natural Killer Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05503134 ↗ |
| Known as | UD-NK | “universal donor mbIL-21 expanded NK cells (UD-NK)” NCT05503134 ↗ |
| Modality | Cell therapy | “adoptive NK cell therapy” NCT05503134 ↗ |